Do you want all the hottest pharmaceutical jobs, latest pharma industry news and up-to-date careers advice straight to your inbox every week? Why not subscribe to the CK Clinical free weekly e- newsletter today!
To subscribe to our e-newsletter, simply enter your email address into the text box found underneath the ‘Subscribe to our newsletter’ text found on the left hand side of this page. Then hit ‘Subscribe me!’ and you’re on your way!
As reported by the Associated Press, the multinational biopharmaceutical company, Celgene has announced that it is planning to buy the biotechnology companyAbraxis BioScience for $2.9billion. The acquisition marks a move by Celgene to boost their presence in oncology.
Abraxis’ cancer drug, Abraxane, is a chemotherapy treatment approved for use in metastic breast cancer. It uses a human protein called albumin, to deliver the chemotherapy, as opposed to other chemography drugs that use chemical solvents, thus eliminating the need for premedication with steroids or antihistamines for hypersensitivity reactions that are caused by chemical solvents. If Abraxane is approved for those other uses, the value of the deal could rise by as much as $3.55 billion.
The PIPA Conference will be taking place at the Cotswold Water Park Four Pillars Hotel in Gloucestershire. The conference is held on an annual basis and provides a great opportunity for both members and non-members to network and share ideas.
The event will be take place on Monday 5th and Tuesday 6th July 2010 and will feature presentations, exhibitions and half-day workshops. The workshops are designed to enhance the skills required in the fields of pharmacovigilance, pharmaceutical information services and in the management of projects and people in the work-place.
If you could like to come along and meet us or enter our competition to win an iPod, our booth number is 4.
If you would like to schedule a private meeting with us at the PIPA Conference to discuss your recruitment plans and see how CK Clinical can help, please do contact Hendre Moolman on 01438 870 023 or email email@example.com.
For more details regarding the PIPA Conference, click here.
As reported on the Guardian website, drugs launched in the last five years account for just 7 per cent of sales from the big pharmaceutical companies.
According to a report by CMR International, the majority of sales from the world’s largest pharmaceutical companies stem from an ageing portfolio of products. This could be due to the patent cliff – meaning that generic drug makers are allowed to produce cheaper versions of the drugs once they have come off patent.
Not only this, but there has been an increase in the number of drug failing in late-stage testing. Infact, the number of products scrapped after reaching final stage of drug development between 2007 and 2009, compared to 2004-2006 has doubled. This decline in success rates has taken its toll on productivity within the pharmaceutical industry.
In order to tackle this, some of the larger pharmaceutical companies are purchasing new medicines from smaller pharmaceutical companies and then teaming up with competitors in a bid to develop new treatments. For example, the pharmaceutical giant, AstraZenecahas undertaken a 50-50 venture with Bristol-Myers Squibb for two new diabetes drugs.
The report by CMR International also found that spending on R&D in the pharmaceutical industry declined by 0.3 per cent last year. This followed a 6.6 per cent drop in 2008.
Anti-cancer drugs, Alzeihmers and diabetes drugs are receiving the most investment.
As reported by Reuters, The Access to Medicines Index (AMI) has announced that European pharmaceutical companies still outrank their U.S rivals in providing drugs to developing countries. They established the lead 2 years ago, however, signs indicate that the gap may well be shrinking.
The global pharmaceutical company, GlaxoSmithKline (GSK) was ranked first in the list of top pharma companies which set out to ensure drugs are made available to the poor. Following GSK came the U.S pharmaceutical company Merck & Co., Switzerland’s Novartis, U.S based Gilead Sciences and France’s Sanofi–Aventis. The AMI is designed to give investors a way of comparing companies social responsibility.
With one week to go, the HR in Pharma Networking Event sponsored by CK Clinical is fast approaching.
The event, which is the first of its kind to take place in the UK, and promises to provide delegates with a useful insight into some of the current issues affecting HR professionals working in the pharmaceutical industry. We hope the event will also give HR professionals a great opportunity to network with their colleagues within the industry.
The HR in Pharma Networking event will be taking place on the morning of Friday 25th June 2010 at the Royal College of Physicians, London.
The schedule for the day is as follows:
9:30am: Arrival and registration followed by a networking opportunity and of course tea and coffee!
10:00am: A presentation by the REC – Quality standards and code of conduct that HR/Recruiters should expect from their recruitment partners followed by Q&A.
10:50am: Tea and coffee break.
11:00am: A presentation by Mike Taylor, an expert in using social media in recruitment. He will be speaking about how you can add value to your recruitment process using social media tools.
12:00pm – Lunch and networking.
1:00pm – Close.
So far confirmed to attend, we have HR Professionals from some of the world’s largest pharmaceutical companies, including Ipsen, Napp, Daiichi Sankyo, Merck Serono, Roche and Quintles and many more.
Places are limited for this unique event, so if this is something you or your colleagues would be interested in please contact Catherine Gutsell at firstname.lastname@example.org to reserve your place.
CK Clinical, the leading specialist pharmaceutical recruitment consultancy, will be attending the GSK Outplacement Event taking place on Wednesday 16th June 2010.
If you are planning to attend and would like some helpful advice to help you find a new job and would like to hear about our current pharmaceutical job vacancies which may be of interest, our specialist consultants Jim Gleeson and Julie Marshall will be happy to help you on the day.
As reported by the BBC News, Quay Pharma, a specialist in testing and designing new products for the pharmaceutical industry plans to create 65 new research and development jobs in Deeside, Wales.
A £2.7 million pharmaceutical facility will be created at the industrial park in Shotton. This will be opened by Deputy First Minister Ieuan Wyn Jones, who announced £784,000 in funding for the facility last year. Speaking of the new development Mr Jones stated: “I am therefore especially pleased that we have been able to offer assistance to the company to facilitate their expansion programme and I hope that their research and development funding will be of further assistance.”
Currently approximately, 15,000 people in Wales work in the healthcare and bioscience sector and the industry is worth £1.3 billion each year to Wales.
Quay Pharma was originally established in 2001 by Professor Mike Rubinstein, former director of the School of Pharmacy at Liverpool John Moores University, and Dave Patterson, a north Wales businessman who has had other pharmaceutical businesses in the area for the last 15 years.
The pharmaceutical company was originally based on the Wirral but expanded and moved its headquarters and manufacturing operations to the industrial park in Deeside in January 2010.
The pharmaceutical giant, GlaxSmithKline (GSK) has denied that hundreds of pharmaceutical jobs are to be cut at it’s plant in Ireland.
GSK employs almost 1,400 people in Ireland. The pharmaceutical company announced that a business review will be conducted at their manufacturing site in Cork but deny that any restructuring or job cuts will take place. A spokesperson from GSK stated, GlaxoSmithKline Cork recently briefed its workforce that as part of its ongoing restructuring programme, first introduced in 2008, it is undertaking a business review at the Cork site which is expected to be completed by the autumn,”
A source at GSK has described media reports indicating that hundreds of pharmaceutical jobs will be cut as ‘completely inaccurate’.
However, pharmaceutical jobs have recently been cut in rival pharmaceutical companies. For example Pfizer has announced it’s plans to close all three of it’s sites in Ireland, with a potential loss of 785 pharmaceutical jobs.
A European Medical Advisor is required to join an established Pharmaceutical company based in Bedfordshire, UK.
As a European Medical Advisor your main role will be to provide a high quality, comprehensive, technical and scientific services for external customers.
Further key responsibilities of this European Medical Advisor job will include:
Acting as key product contact for internal colleagues and contacts.
Delivering a reactive enquiry service for designated products – maintaining high technical and ethical promotional standards and appropriate time and quality standards.
Maintaining core reference documents for use by European Medical Information colleagues.
Maintaining global Q&A’s on the specified products on the QUEST database, ensuring that these are kept updated, added or deleted as appropriate.
Liaising with European Medical Affairs Directors and others as necessary to ascertain and deliver Medical Information outputs appropriate for product, lifecycle and markets.
Maintaining Therapeutic Area and product knowledge to a high standard – act as the European MI Therapy Area contact.
Liaising with other Regional Medical Information Groups as appropriate.
Sharing best practice across the regional Medical Information community.
Identifying the need and coordinating with other teams to deliver Medical Information product and skills training to colleagues within the European region in line with the European MI Training Programme.
Being responsible for identifying the need for and providing or co-ordinating Medical Information specific training for European colleagues on products and business-critical systems.
The role holder and colleagues will be responsible as a team for cascading information on these systems and to provide advice on how to use them effectively, to MI staff within Europe. <p>
Making sure that appropriate enquiry details are logged in the regional enquiry management database for all enquiries received.
Identifying and defining needs for literature resources and copyright information and communicate these to the company Library contact.
Be responsible for representing the European region for certain areas, informing colleagues of Medical Information issues across the company and sharing best practice within the Medical Information arena.
The ideal candidate for this European Medical Advisor job will hold the following qualifications and experience:
Previous experience working in Medical information.
Degree in pharmacy, or biological, pharmaceutical or life science.
Experience of working as part of a team.
Proficient in use of MS Office.
Knowledge of the ABPI and other codes and guidelines.
Experience working as a second-line (or at least, first line) European Medical Advisor with strong evidence of successful delivery/ management.
For more information, or to apply for this European Medical Advisor job, please contact Hendre Moolman at CK Clinical on +44 (0)1438 870 023 or email email@example.com quoting 19919 to indicate your interest.